{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-097091","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2026-08-14T20:05:42+00:00","discovered_at":"2026-08-14T20:12:00.474959+00:00","generated_at":"2026-08-14T20:12:23.664149+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Annovis fully enrolls Phase 3 AD trial with 850 patients; Q2 net loss $0.40/share","bullets":["Pivotal Phase 3 AD trial fully enrolled with 850 patients, exceeding original target of 760; topline symptomatic data expected Q1 2027.","PD OLE study enrolled 266 of 500 patients; full enrollment projected Q4 2026; 26 US sites activated.","Q2 2026 net loss $0.40/share vs $0.32 in Q2 2025; R&D spend $12.0M vs $5.2M YoY.","Cash $18.7M at June 30, 2026 vs $19.5M at Dec 31, 2025; 42.6M shares outstanding.","Cheng Fang, Ph.D. promoted to Chief Scientific Officer; AD OLE study to initiate October 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-097091","json":"https://secwatch.observer/filing/0001104659-26-097091.json","markdown":"https://secwatch.observer/filing/0001104659-26-097091.md","text":"https://secwatch.observer/filing/0001104659-26-097091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/0001104659-26-097091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:12:23.664149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}